» Articles » PMID: 31293500

Cell-Based Therapies for Stroke: Are We There Yet?

Overview
Journal Front Neurol
Specialty Neurology
Date 2019 Jul 12
PMID 31293500
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Stroke is the second leading cause of death and physical disability, with a global lifetime incidence rate of 1 in 6. Currently, the only FDA approved treatment for ischemic stroke is the administration of tissue plasminogen activator (tPA). Stem cell clinical trials for stroke have been underway for close to two decades, with data suggesting that cell therapies are safe, feasible, and potentially efficacious. However, clinical trials for stroke account for <1% of all stem cell trials. Nevertheless, the resources devoted to clinical research to identify new treatments for stroke is still significant (53-64 million US$, Phase 1-4). Notably, a quarter of cell therapy clinical trials for stroke have been withdrawn (15.2%) or terminated (6.8%) to date. This review discusses the bottlenecks in delivering a successful cell therapy for stroke, and the cost-to-benefit ratio necessary to justify these expensive trials. Further, this review will critically assess the currently available data from completed stroke trials, the importance of standardization in outcome reporting, and the role of industry-led research in the development of cell therapies for stroke.

Citing Articles

Advancements in the mechanisms of Naotai formula in treating stroke: A multi-target strategy.

Shi Y, Ma Y, Liao J Heliyon. 2024; 10(17):e36748.

PMID: 39296232 PMC: 11408019. DOI: 10.1016/j.heliyon.2024.e36748.


Stem cell therapy: a new hope for stroke and traumatic brain injury recovery and the challenge for rural minorities in South Carolina.

Mohamed G, Lench D, Grewal P, Rosenberg M, Voeks J Front Neurol. 2024; 15:1419867.

PMID: 39184380 PMC: 11342809. DOI: 10.3389/fneur.2024.1419867.


Brain repair mechanisms after cell therapy for stroke.

Rust R, Nih L, Liberale L, Yin H, El Amki M, Ong L Brain. 2024; 147(10):3286-3305.

PMID: 38916992 PMC: 11449145. DOI: 10.1093/brain/awae204.


Preconditioning with interleukin-1 alpha is required for the neuroprotective properties of mesenchymal stem cells after ischemic stroke in mice.

Wong R, Smith C, Allan S, Pinteaux E J Cereb Blood Flow Metab. 2023; 43(12):2040-2048.

PMID: 37602422 PMC: 10925871. DOI: 10.1177/0271678X231197109.


Impact of caregivers' psychological and caregiving status on recruitment, conversion, and retention in stem cell therapy trials for cerebral palsy: A prospective survey analysis.

Huang X, Qin X, Li M, Li Y, Shen L, Jin G Nurs Open. 2023; 10(8):5293-5305.

PMID: 37431277 PMC: 10333896. DOI: 10.1002/nop2.1767.


References
1.
Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn K, Gebel J . Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000; 55(4):565-9. DOI: 10.1212/wnl.55.4.565. View

2.
Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M . Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci. 2001; 189(1-2):49-57. DOI: 10.1016/s0022-510x(01)00557-3. View

3.
Hess D, Hill W, Martin-Studdard A, Carroll J, Brailer J, Carothers J . Bone marrow as a source of endothelial cells and NeuN-expressing cells After stroke. Stroke. 2002; 33(5):1362-8. DOI: 10.1161/01.str.0000014925.09415.c3. View

4.
Bekelman J, Li Y, Gross C . Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003; 289(4):454-65. DOI: 10.1001/jama.289.4.454. View

5.
Ashjian P, Elbarbary A, Edmonds B, DeUgarte D, Zhu M, ZuK P . In vitro differentiation of human processed lipoaspirate cells into early neural progenitors. Plast Reconstr Surg. 2003; 111(6):1922-31. DOI: 10.1097/01.PRS.0000055043.62589.05. View